Weekly Funding Opportunities

[Med Research]

American Cancer Society: Role of Health Policy and Health Insurance in Improving Access to and Performance of Cancer Prevention, Early Detection, and Treatment Services<https://urldefense.proofpoint.com/v2/url?u=https-3A__www.cancer.org_research_we-2Dfund-2Dcancer-2Dresearch_apply-2Dresearch-2Dgrant_grant-2Dtypes_rfa-2Drole-2Dhealthcare-2Dinsurance-2Dcancer.html&d=DwIFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=SbFASzg89DMnenjZskcUb-uKh2diB5h-VtUMtf8ySSI&s=9o67nLbs0jE6H50Euv5NWLJB5j2bDaApXlfMXPIkqzM&e=>
The American Cancer Society is accepting proposals for research projects with the potential to generate new knowledge of the effects of the United States healthcare system structure and the role of insurance in both access to and the outcomes of cancer screening, early detection, and treatment services.
ACS is keenly interested in supporting rapid learning research on the effects of health policy changes on patients, providers, and health systems. This includes but is not limited to facilitators and barriers to care; unintended consequences; differential experiences and outcomes of patients seeking or receiving care; best practice models for quality care; and economic impact. Awards will not exceed $200,000 per year (direct costs) for up to four years.
Due April 1, 2019 and October 15, 2019. Med-RA deadline to receive draft documents for the April deadline: March 18.

Complications of Pediatric Type 1 Diabetes (T1D) - Planning Cooperative Agreements (U34 Clinical Trial Not Allowed)<https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DDK-2D18-2D007.html&d=DwIFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=SbFASzg89DMnenjZskcUb-uKh2diB5h-VtUMtf8ySSI&s=yIhqa5s3pX97KiLc1_TN0SDVqOdHWgk_CrRWvG-XyrU&e=>
This FOA invites applications for planning cooperative agreements (U34) for a national, multisite, observational cohort study to prospectively examine the risk and protective factors for neurocognitive complications of pediatric type 1 diabetes (T1D; onset approximately ages 5-10 years) and a comparison sample. The U34 is designed to: 1) Permit early peer review of the rationale for the proposed cohort study; 2) Permit assessment of the study design; and 3) Provide support for the development of essential elements required for the design and conduct of the cohort study and the management and analysis of the study data. Consultation with NIDDK scientific staff is strongly encouraged prior to the submission of the U34 application.
Due April 11, 2019. Med-RA deadline to receive draft documents: March 28.

Whitehall Foundation Grant Programs: Basic Biological Research<https://urldefense.proofpoint.com/v2/url?u=http-3A__www.whitehall.org_applying_&d=DwIFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=SbFASzg89DMnenjZskcUb-uKh2diB5h-VtUMtf8ySSI&s=dqXJ3d1Aos67WmPT1NDDVlhkWlacQ5oNeSiadL9I_cU&e=>
It is the Whitehall Foundation's policy to assist those dynamic areas of basic biological research that are not heavily supported by federal agencies or other foundations with specialized missions. The Whitehall Foundation is currently interested in basic research in neurobiology, defined as follows: Invertebrate and vertebrate (excluding clinical) neurobiology, specifically investigations of neural mechanisms involved in sensory, motor, and other complex functions of the whole organism as these relate to behavior. The overall goal should be to better understand behavioral output or brain mechanisms of behavior. The Whitehall Foundation does not support research focused primarily on disease(s) unless it will also provide insights into normal functioning. Research grants are available to established scientists of all ages working at accredited institutions in the United States. Applications will be judged on the scientific merit and the innovative aspects of the proposal as well as on the competence of the applicant. Research grants of up to three years will be provided. A renewal grant with a maximum of two years is possible, but it will be awarded on a competitive basis. Research grants will not be awarded to investigators who have already received, or expect to receive, substantial support from other sources, even if it is for an unrelated purpose. Research grants normally range from $30,000 to $75,000 per year. Grants-in-Aid program is designed for researchers at the assistant professor level who experience difficulty in competing for research funds because they have not yet become firmly established. Grants-in-Aid can also be made to senior scientists. All applications will be judged on the scientific merit and innovative aspects of the proposal, as well as on past performance and evidence of the applicant's continued productivity. Grants-in-Aid are awarded for a one-year period and do not exceed $30,000.
Letter of intent due April 15, 2019 and October 1, 2019. Med-RA deadline to receive draft documents for the April deadline: April 1.

Health Effects Institute: Rosenblith New Investigator Award<https://urldefense.proofpoint.com/v2/url?u=https-3A__www.healtheffects.org_research_funding_rosenblith-2Daward&d=DwIFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=SbFASzg89DMnenjZskcUb-uKh2diB5h-VtUMtf8ySSI&s=x7iJyT44mixm0LtZTv2yiz3RvIWHw8kgB_EezfWvvWA&e=>
The Health Effects Institute (HEI) is a nonprofit corporation chartered in 1980 as an independent research organization to provide high-quality, impartial, and relevant science on the health effects of air pollution. As part of its mission, HEI established the Walter A. Rosenblith New Investigator Award to provide funding for outstanding investigators who are beginning their independent research careers. By providing financial support for investigators at an early point in their careers, the institute hopes to encourage highly qualified individuals to undertake research on the health effects of air pollution.
Each award will be up to $150,000 per year, with a maximum of $450,000 over three years. The funds can be used to provide salary support for the investigator and supporting junior personnel as well as operating costs, including supplies and equipment.
Scientists of any nationality holding a PhD, ScD, MD, DVM, or DrPH degree or equivalent are eligible to apply. At the time of application, the candidate should have two to seven years of research experience after obtaining the highest degree and must be in an assistant professor or equivalent position in an academic or research institution.
Preliminary applications due April 15, 2019. Med-RA deadline to receive draft documents: April 1.

Mechanistic studies on chronic alcohol use and sleep homeostasis (R01 Clinical Trial Optional)<https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DAA-2D19-2D006.html&d=DwIFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=SbFASzg89DMnenjZskcUb-uKh2diB5h-VtUMtf8ySSI&s=Li6PAiJnBQSaSRiGFQ7l9B5WfFQDTqPE9cAxr5i3TdQ&e=>
This Funding Opportunity Announcement (FOA), issued by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), encourages Research Project Grant (R01) applications proposing to conduct mechanistic studies on the relationships between sleep problems and alcohol dependence. A major impediment for recovery from alcohol use disorder (AUD) is the persistent sleep problems during abstinence promoting relapse. The objective of this FOA is to promote research in animal models and human subjects on the reciprocal relationships between chronic alcohol use and sleep disruptions. The major goal is to understand the underlying mechanisms that will lead to improved treatments for alcohol dependence. NIAAA strongly encourages collaborative efforts between experts in sleep research and established alcohol investigators to facilitate the development of applications incorporating both areas of research. Projects measuring acute effects of alcohol, circadian changes and observational studies will not be considered responsive to this FOA.
Due April 17, 2019. Med-RA deadline to receive draft documents: April 3.

Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Obesity Research (U01 Clinical Trial Not Allowed)<https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DDK-2D19-2D001.html&d=DwIFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=SbFASzg89DMnenjZskcUb-uKh2diB5h-VtUMtf8ySSI&s=oes_BpYFW3_S267SU8nqlI96OQ_ryLPZ60O-jxHDj_0&e=>
This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing the development of targeted mass spectrometric assays (e.g., Multiple Reaction Monitoring) for proteins and peptides of primary interest to the obesity research community (e.g., Adiponectin, Leptin, Resistin, Neuropeptide Y, Alpha-melanocyte-stimulating hormone, Peptide YY, Glucagon-like peptide 1, Ghrelin, Adrenocorticotropin, Corticotropin-releasing hormone, Gastrin, Cholecystokinin, Secretin, Vasoactive intestinal peptide, gastric-inhibitory peptide, gastrin-releasing peptide, motilin, pancreatic polypeptide, RBP4, myostatin, FGF21).  The proposed assays should be highly reproducible, easily transferable to other laboratories, easy to multiplex, and validated in human plasma or serum.
Due April 17, 2019. Med-RA deadline to receive draft documents: April 3.

Refinement and Testing of Interventions to Sustain ADHD Treatment Effects Across Settings and Developmental Transitions (R34 Clinical Trial Required)<https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DMH-2D20-2D100.html&d=DwIFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=SbFASzg89DMnenjZskcUb-uKh2diB5h-VtUMtf8ySSI&s=T8oK7F1ZWzuGYWwocHA57TdFaTIu2JOZtMKcq50qO74&e=>
NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of augmented or modified interventions designed to promote sustained improvement in attention-deficit/hyperactivity disorder (ADHD) symptoms and functional impairments across settings and transitions in children, adolescents, and young adults. An emphasis is placed on trials that go beyond seeking incremental gains in intervention effects, and instead take a theory-driven, empirical approach to applying modifications that will have a significant and enduring impact on functioning. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target mechanism(s) presumed to underlie the intervention effects; and to obtain necessary preliminary data as a pre-requisite to a larger-scale, definitive effectiveness trial.
Due May 1, 2019 and November 15, 2019. Med-RA deadline to receive draft documents for the May deadline: April 17.

Secondary Data Analysis to Examine Long-Term and/or Potential Cross-Over Effects of Prevention Interventions: What are the Benefits for Preventing Mental Health Disorders? (R01 Clinical Trial Not Allowed)
R01<https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DMH-2D20-2D110.html&d=DwIFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=SbFASzg89DMnenjZskcUb-uKh2diB5h-VtUMtf8ySSI&s=x8UFVM0K6moFkcbJcaqjDhi53SUpXBmsYfdyGx8-xYM&e=>
The purpose of this funding opportunity announcement (FOA) is to encourage research to integrate/harmonize existing data sets from preventive intervention trials implemented early in life to: 1) examine risk and protective factors relevant to later mental health outcomes in childhood, adolescence and young adulthood; and 2) determine whether preventive interventions delivered earlier in life have long-term effects, and/or cross-over effects (e.g., unanticipated beneficial effects), on important mental health outcomes, including serious mental illness (e.g., depression, anxiety, suicide ideation and behaviors, psychosis behaviors).
Due May 2, 2019 and January 2, 2020. Med-RA deadline to receive draft documents for the May deadline: April 18.

Computational Models of Immunity (U01 Clinical Trial Not Allowed)<https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DAI-2D19-2D011.html&d=DwIFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=SbFASzg89DMnenjZskcUb-uKh2diB5h-VtUMtf8ySSI&s=q1jlRBMJeaXe1Ti_cB20fyUXXoe0FbXUfcOtKpZqrIc&e=>
This Funding Opportunity Announcement (FOA) solicits applications developing computational models of immunity that advance understanding of the mechanisms required to induce and/or maintain protective immunity to infectious pathogens, other than HIV, and/or vaccines against such pathogens. The main goal of this FOA is to advance development and application of computational models of immunity that are refined through iterative immunological experimentation to validate and improve the utility and robustness of the computational models. Another goal of this FOA is to make the computational models and data developed under this initiative readily available to the broader research community for further refinement or direct use in biological experimentation. This program will also support workshops and symposia to foster the use of computational models of immunity by the broader research community.
Due June 10, 2019. Med-RA deadline to receive draft documents: May 28.

To search for additional funding opportunities, please visit CoM's unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.




-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20190215/b04c0369/attachment.html>